EGFR and non-small cell lung carcinoma: At the present time, data on the use of single agent ICB in the first-line treatment of EGFR-mutant NSCLC have been published by Lisberg et al. and suggest a total lack of efficacy of pembrolizumab in the initial ‘naïve’ setting despite the presence of PD-L1 expression ≥ 1% [13].